Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 billion

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 23, 2024 at 10:52: AM
via French healthcare company Sanofi has agreed to buy U.S. biotech firm Inhibrx in a deal valued at up to $2.2 billion, bolstering its drug development portfolio with an experimental treatment for a rare genetic disease.

article source
 

<



Similar threads

cafead
Sanofi weighs Mirati buy as KRAS cancer drug battle enters new phase
Replies
0
Views
230
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi to buy Origimm Biotechnology for acne vaccine candidate
Replies
0
Views
154
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2 billion deal
Replies
0
Views
104
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi, seeking control of key drug, to buy Principia for $3.7B
Replies
0
Views
187
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
What Sanofi Might Buy With Its Regeneron Windfall
Replies
1
Views
189
Pharma/Biotech Companies - In the News
anonymous
Top Bottom
Back
Quote